Patheon

Rebranded Liquified Agency Unveils Expansion to South Florida With Focus as Full-Service Independent Ad Agency

Retrieved on: 
Wednesday, March 6, 2024
Giant, Giant Food, Marketing, Growth, Patheon, Creative director, Advertising, Liquefaction, Acceleration, CoStar Group, National Geographic, Industrial design

SARASOTA, Fla., March 6, 2024 /PRNewswire/ -- Liquified Agency, formerly Liquified Creative, an award-winning full-service independent advertising agency, recently announced the launch of their official company rebrand, including an evolved moniker, brand identity, and enhanced website. With offices in Annapolis, Maryland, and Sarasota, Florida, the company will now be known as Liquified Agency to more accurately reflect its broad range of branding, marketing, web, and public relations services for national, regional, and local clients.

Key Points: 
  • SARASOTA, Fla., March 6, 2024 /PRNewswire/ -- Liquified Agency, formerly Liquified Creative, an award-winning full-service independent advertising agency, recently announced the launch of their official company rebrand, including an evolved moniker, brand identity, and enhanced website.
  • "As a full-service creative ad agency, our own brand sets the standard for what we can offer our clients," Wiggins stated.
  • "Rebranding to Liquified Agency encapsulates our redefined approach to creative communication services, all within a fresh and dynamic identity that retains our unwavering passion.
  • Despite the expansion, Maryland remains Liquified's home base, and the company plans to prioritize business growth in both locales.

NightHawk Biosciences Announces Planned Name Change to Scorpius Holdings, Reflecting Successful Transition to a Large Molecule Biomanufacturing CDMO

Retrieved on: 
Monday, January 8, 2024
Marketing, Associate, PEGylation, Commercial, Biotechnology, Spacecraft, Pennsylvania State University, Quality management system, Binghamton University, Ania, Control, Technology transfer, Annual report, Robert Morris University, CMC, Lehigh University, University, Region, Doctor of Philosophy, Therapy, Scorpius, PPQ, Patheon, Chemical engineering, Rutgers University, Computer science, Biochemical engineering, Research, GMP, WuXi AppTec, Business development, Quality assurance, Growth, Investment, Bristol Myers Squibb

The Company will continue to operate its CDMO within the Scorpius BioManufacturing subsidiary.

Key Points: 
  • The Company will continue to operate its CDMO within the Scorpius BioManufacturing subsidiary.
  • Jeff Wolf, CEO of Nighthawk, commented, “Our rebranding to Scorpius Holdings is a testament to our successful transition and the growth of our CDMO operations.
  • The industry faces a critical shortage of clinical-scale biologic manufacturing capacity, driven by increasing demand for large molecule CDMO services.
  • Our state-of-the-art facility in San Antonio, Texas ideally positions us to address this gap in CDMO manufacturing capacity and services.

Global Small Molecule Innovator CDMO Market Poised for Strong 6.5% CAGR Through 2031, Fueled by Rising Outsourcing Demand in Pharmaceutical Development - ResearchAndMarkets.com

Retrieved on: 
Wednesday, October 18, 2023
Other Science, Science, Molecule, Drug development, Pharmaceutical innovations, Infection, Metabolic disorder, Lonza Group, Catalent, Confidentiality, Small molecule, Therapy, Recipharm, Johnson & Johnson Pharmaceutical Research and Development, Patheon, European Journal of Pharmaceutical Sciences, Neurology, Metabolism, CDMO, Research, Journal, Outsourcing, Pharmacy, Growth, Respiratory disease, COVID-19, Commercial, Cardiovascular disease, Cambrex Corporation, Thermo Fisher Scientific, Clinical pharmaceutical scientist, Small, Flexible, Intellectual property, IP, Compound annual growth rate, AAPS, Fine chemical, Pharmaceutical industry, Biotechnology

Increasing Demand for Outsourcing Services in Drug Development: Pharmaceutical companies are increasingly outsourcing complex and resource-intensive processes such as drug substance synthesis and drug product manufacturing to CDMOs.

Key Points: 
  • Increasing Demand for Outsourcing Services in Drug Development: Pharmaceutical companies are increasingly outsourcing complex and resource-intensive processes such as drug substance synthesis and drug product manufacturing to CDMOs.
  • Intellectual Property and Confidentiality Concerns: Intellectual property (IP) and confidentiality concerns pose a restraint on the Small Molecule Innovator CDMO market.
  • The Small Molecule Innovator CDMO market is segmented into product types, stage types, customer types, therapeutic areas, and regions.
  • Notable segments include:
    Product: Small Molecule API and Small Molecule Drug Product, with Small Molecule API exhibiting the highest CAGR during the forecast period.

Vertex Appoints Michel Lagarde to its Board of Directors

Retrieved on: 
Thursday, October 5, 2023
Biotechnology, Pharmaceutical, Genetics, Health, Vertex Pharmaceuticals, JLL Partners, JLL, Thermo Fisher Scientific, Cystic fibrosis, VRTX, Lagarde, BBA, Bachelor of Business Administration, History, Business administration, Philips, Patient, Management, Vertex, Patheon, EU Business School

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Michel Lagarde has been appointed to its Board of Directors as an independent director.

Key Points: 
  • Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Michel Lagarde has been appointed to its Board of Directors as an independent director.
  • Mr. Lagarde is a senior health care and business leader with global expertise, currently serving as Chief Operating Officer and Executive Vice President of Thermo Fisher Scientific Inc.
  • “We are delighted to have Michel join the Vertex Board.
  • “Vertex is at a very exciting time in its history as it builds on its success in cystic fibrosis using its serial innovation strategy,” said Michel Lagarde.

BioCentriq® Expands its Executive Leadership Team with Appointment of Jennifer Manning as Chief Commercial Officer

Retrieved on: 
Tuesday, October 3, 2023
Human Genome Sciences, Trade, Executive director, Central Waqf Council, Fujifilm Diosynth Biotechnologies, Health policy, Patheon, Abbott Laboratories, CBM, Biology, Clemson University, CDMO, Patient, AbbVie, Growth, MPA, Commercial, Therapy, SVP, Management, Fine chemical, New York University

NEWARK, N.J., Oct. 3, 2023 /PRNewswire/ -- BioCentriq, a cell therapy CDMO (contract development and manufacturing organization), announced today the appointment of Jennifer Manning, MPA, as its Chief Commercial Officer, effective October 3, 2023.

Key Points: 
  • NEWARK, N.J., Oct. 3, 2023 /PRNewswire/ -- BioCentriq, a cell therapy CDMO (contract development and manufacturing organization), announced today the appointment of Jennifer Manning, MPA, as its Chief Commercial Officer, effective October 3, 2023.
  • Ms. Manning added, "I am honored and excited to join the BioCentriq leadership team.
  • Before joining CBM, she held the position of Executive Director, Commercial Development at Fujifilm Diosynth Biotechnologies, where she was responsible for building and leading the North American Advanced Therapies commercial development team.
  • Earlier in her career, Ms. Manning held commercial roles of increasing responsibility at Lonza, Alcami Corporation, Patheon, and DSM Biologics.

Matica Bio Appoints Life Sciences Veterans Laura Parks, Heather N. Sugrue to Top Leadership Positions

Retrieved on: 
Thursday, September 14, 2023
Science, Other Science, Biotechnology, Research, Other Manufacturing, Health, Genetics, Manufacturing, Immortalised cell line, GMP, Bachelor of Science in Human Biology, Ohio State University, DSM, Drug development, University, CGT, Patheon, Matica, Marketing, Ithaca College, Multimedia, Medicine, Catalent, Boston University, Society, Park, Chemistry, CDMO, Patient, Syngeneic stem cell transplantation, Sugrue, Growth, Commercial Operating System, Pharmaceutical industry, Management, Fine chemical

View the full release here: https://www.businesswire.com/news/home/20230914717415/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230914717415/en/
    Heather N. Sugrue, VP of Alliance Management at Matica Bio (Photo: Business Wire)
    Parks will drive Matica Bio’s commercial efforts, including sales team development, marketing, and strategy.
  • She brings to the company more than two decades of business leadership experience, driving the development of high-performance, market-focused teams in the life sciences.
  • Prior to Matica Bio, Parks served in senior roles for several life science companies and CDMOs, including Patheon Pharmaceuticals, where she led strategic commercial efforts, integrating diverse service offerings and driving global pricing initiatives.
  • “Their expertise will be an invaluable addition to Matica Bio as we serve our clients through our innovative manufacturing solutions in this rapidly growing industry.”

Global Formulation Development Outsourcing Market Poised for Substantial Growth from 2023 to 2028 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, September 5, 2023
Biotechnology, Pharmaceutical, Health, Quotient, Charles River Laboratories, Maintenance, Drug, Drug development, Lonza Group, Patheon, Marketing, Biocon, Lonza, Clinical trial, Emergent, Research, Thermo Fisher Scientific, Competition, Public expenditure, CDMO, Complexity, Patent, MUFG Americas Holdings Corporation, Intertek, Drug discovery, Spray drying, Growth, Catalent, Formulation, Micronization, Complex, Fine chemical, Pharmaceutical industry

The Formulation Development Outsourcing Market is projected to experience substantial growth during the forecast period from 2023 to 2028.

Key Points: 
  • The Formulation Development Outsourcing Market is projected to experience substantial growth during the forecast period from 2023 to 2028.
  • Cost Savings: One of the primary drivers of growth in the Global Formulation Development Outsourcing Market is cost savings.
  • Increased Complexity of Drug Development: The complexity of drug development is driving the growth of the Formulation Development Outsourcing Market.
  • The comprehensive Global Formulation Development Outsourcing Market report covers market segmentation by product and service, application, and end-use, providing valuable insights into the market's current state and future prospects.

NorthStar Medical Radioisotopes Expands Management Team with Appointment of Jean-Noel David, MBA, MS, as Vice President, Operations

Retrieved on: 
Tuesday, April 18, 2023
Oncology, Health, Other Health, General Health, Radiology, Pharmaceutical, Biotechnology, IBM, Transformation, Patheon, Senior, Radionuclide, Engineering, Thermo Fisher Scientific, Mechanical engineering, Radiopharmaceutical, MBA, Multimedia, CMO, Mechanical, MS, Implementation, NorthStar, CDMO, Government of Dubai Media Office, Pleasure, Catalent, Shijiazhuang Pharma Group, Management, Operation

NorthStar Medical Radioisotopes , LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic and medical imaging applications, has announced the appointment of Jean-Noel David, MBA, MS, as Vice President, Operations.

Key Points: 
  • NorthStar Medical Radioisotopes , LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic and medical imaging applications, has announced the appointment of Jean-Noel David, MBA, MS, as Vice President, Operations.
  • Mr. David will have company-wide responsibility for Engineering, Manufacturing and Project Management, and report to President and Chief Operating Officer Frank Scholz, Ph.D.
  • View the full release here: https://www.businesswire.com/news/home/20230418005138/en/
    NorthStar Medical Radioisotopes has expanded its management team with the appointment of Jean-Noel David, MBA, MS, as Vice President, Operations.
  • Previous to that, he was a senior management consultant with IBM, and Implementation Director for the Government of Dubai.

Aseptic Fill Finish Global Market Report 2023: Growing Demand for Aseptic Fill Finish Services Bolsters Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, April 11, 2023
Chemicals, Plastics, Manufacturing, Molecule, Vaccine, APL, Charles River Laboratories, Hetero Drugs, Partnership, Fresenius (company), Patheon, Powder, Lonrho, Overalls, Research, Antibody, Type, Organization, Zenith Contract Services, Protein, Risk, Peptide, Approved Drug Products with Therapeutic Equivalence Evaluations, WuXi Biologics, Health, Robotics, Intas Pharmaceuticals, Oligonucleotide, Safety, Syringe, Fine chemical, Marketing, Glass, Airline, Oil

The report features an extensive study of the current market landscape and future opportunity for the aseptic fill finish service providers.

Key Points: 
  • The report features an extensive study of the current market landscape and future opportunity for the aseptic fill finish service providers.
  • In fact, a number of companies are involved in offering biologics fill finish services and small molecule fill finish services.
  • Answer: The global aseptic fill finish services market is expected to grow at a CAGR of 7%, during the period 2023-2035.
  • Answer: Presently, the vials (67%) account for the largest share in the global aseptic fill finish services market.

Advent International Appoints Biopharma Executive James Mullen as Operating Partner

Retrieved on: 
Tuesday, March 28, 2023
Professional Services, Health, Finance, Asset Management, Pharmaceutical, Biotechnology, Patent, Bachelor of Science in Human Biology, Executive, Pronova BioPharma, International, Cas9, MBA, Research, DSM-IV codes, Villanova University, Thermo Fisher Scientific, Cas12a, Rensselaer Polytechnic Institute, Patient, Chemical engineering, Advent, Advent International, Knowledge, Biogen, Fine chemical, Pharmaceutical industry, Science, Patheon, Editas Medicine

Advent International (“Advent”), one of the largest and most experienced global private equity investors, today announced the appointment of seasoned biopharma executive James (“Jim”) Mullen as an Operating Partner.

Key Points: 
  • Advent International (“Advent”), one of the largest and most experienced global private equity investors, today announced the appointment of seasoned biopharma executive James (“Jim”) Mullen as an Operating Partner.
  • “Jim has been a renowned leader in the biopharma sector for over four decades,” said John Maldonado, Managing Partner at Advent.
  • Mullen currently serves as the Executive Chairman of Editas Medicine, a leading genome editing company, where he previously served as the company’s President and CEO.
  • Mullen served as the CEO and director of Patheon, a pharmaceutical and manufacturing organization serving the pharmaceutical and biotechnology sectors.